蛋白质组和网络药理学整合确定了sunitinib作为2型糖尿病点的潜在治疗药物
Yuan Kong1, Hai-Wei Zhu1, Hui-Xin Tong1
1Department of Metabolism and Endocrinology, General Hospital of Northern Theater Command, Shenyang, China.
Therapeutic advances in endocrinology and metabolism
|October 28, 2025
概括
这项全蛋白质组研究确定了2型糖尿病 (T2D) 的新疗法标. 苏尼蒂尼布成为T2D治疗的有希望的候选药物,需要进一步的临床研究.
科学领域:
- 遗传学和基因组学 遗传学和基因组学
- 生物标志物发现发现
- 药理学 药理学是指药理学的学科.
背景情况:
- 蛋白质组对于识别新的治疗点至关重要.
- 门德尔随机化 (MR) 分析为大规模蛋白质组数据中的因果推理提供了一个强大的方法.
研究的目的:
- 进行全蛋白质组门德尔随机化 (MR) 分析,以确定潜在的2型糖尿病 (T2D) 生物标志物和治疗点.
- 评估已识别的蛋白质标的药用性和表达.
主要方法:
- 使用逆变量加权MR与deCODE Genetics和FinnGen.数据一起使用.
- 采用反向MR,外部队列验证和贝叶斯加权MR以获得强度.
- 进行了蛋白质-蛋白质相互作用 (PPI) 网络分析,途径丰富,药物可用性和单细胞表达分析.
主要成果:
- 鉴定了233种与T2D风险相关的蛋白质,15种在FDR校正后仍然显著.
- TPST2和CHRDL1被强调为有前途的治疗点.
- 因果蛋白涉及炎症,氧化应激,动脉样硬化和细胞内信号传递;苏尼替尼针对多个已识别的枢纽基因.
结论:
- 这项研究成功地确定了2型糖尿病 (T2D) 的新疗法目标.
- 苏尼蒂尼布作为T2D的潜在治疗剂,需要在临床试验中进一步验证.
相关概念视频
Protein Networks
4.5K
An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
4.5K
Transducer Mechanism: Enzyme-Linked Receptors
3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.8K
Glucagon-like Receptor Agonists
836
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
836
Oral Hypoglycemic Agents: Biguanides and Glitazones
581
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
581
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Dipeptidyl Peptidase 4 Inhibitors
575
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
575

